CX-2043, an EpCAM-targeting probody drug conjugate,...

European Journal of Cancer 2020 / 10 Vol. 138

CX-2043, an EpCAM-targeting probody drug conjugate, demonstrates anti-tumor activity with a favorable safety profile in preclinical models

Liu, B., Shen, J., Yu, W., Jing, C., Saha, S., Rangan, V., Richardson, J., Liu, Y., Boule, S., Lucas, J., Ab, O., Hicks, S., Belvin, M., Kavanaugh, M., Schleyer, S.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
138
Journal:
European Journal of Cancer
DOI:
10.1016/S0959-8049(20)31104-7
Date:
October, 2020
File:
PDF, 175 KB
2020
Conversion to is in progress
Conversion to is failed